Torii M, Kanai K, Watabe H, Oka H, Oda T
Gan. 1980 Feb;71(1):24-9.
The effect of BCG, an immunopotentiator, on the hepatocarcinogenesis of the rat induced by 3'-methyl-4-(dimethylamino)azobenzene (3'-Me-DAB) was investigated. After administration of 3'-Me-DAB for 6 weeks, BCG was injected to the rats at 2-week intervals for 50 weeks and the serial determinations of serum alpha-fetoprotein and morphological examination of the liver were made. In the control group, the second rise of serum alpha-fetoprotein, which reflected the occurrence of hepatoma, was seen at about 12 weeks after discontinuance of 3'-Me-DAB. On the other hand, the second rise of serum alpha-fetoprotein in the group treated with BCG was delayed about 10 weeks compared to control group, although there was no significant difference in the final incidence of hepatomas between these two groups. Infiltration of the lymphocytes was observed in the liver of rats treated with BCG without hepatoma. BCG seems to have an inhibitory effect on 3'-Me-DAB carcinogenesis of the rat, possibly by stimulating the cell-mediated immunity, although it is not strong enough to prevent the occurrence of hepatoma completely.
研究了免疫增强剂卡介苗(BCG)对3'-甲基-4-(二甲基氨基)偶氮苯(3'-Me-DAB)诱导的大鼠肝癌发生的影响。给大鼠连续6周给予3'-Me-DAB后,每隔2周给大鼠注射BCG,持续50周,并对血清甲胎蛋白进行系列测定以及对肝脏进行形态学检查。在对照组中,反映肝癌发生的血清甲胎蛋白第二次升高在停止给予3'-Me-DAB后约12周出现。另一方面,与对照组相比,接受BCG治疗组的血清甲胎蛋白第二次升高延迟了约10周,尽管这两组肝癌的最终发生率没有显著差异。在未发生肝癌的接受BCG治疗的大鼠肝脏中观察到淋巴细胞浸润。卡介苗似乎对大鼠的3'-Me-DAB致癌作用有抑制作用,可能是通过刺激细胞介导的免疫,尽管其抑制作用不足以完全防止肝癌的发生。